$KPRX
KIORA PHARMACEUTICALS INC Stock $kprx

$kprx Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-K Financial Statement

#000114420416091485 Filed on March 30, 2016

Income Statement

Concept	2016 Q1	2015	2014 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.530M	$3.960M	$280.0K
YoY Change	96.15%	105.18%	-44.0%
% of Gross Profit
Research & Development	$914.0K	$2.717M	$110.0K
YoY Change	184.34%	411.59%	-15.38%
% of Gross Profit
Depreciation & Amortization	$84.00	$1.257K	$0.00
YoY Change	-75.44%	-27.09%	-100.0%
% of Gross Profit
Operating Expenses	$2.443M	$6.678M	$390.0K
YoY Change	121.21%	171.22%	-38.1%
Operating Profit
YoY Change
Interest Expense	$0.00	$1.934M	$40.00K
YoY Change	-100.0%	337.95%	-122.22%
% of Operating Profit
Other Income/Expense, Net	$317.00	-$1.710M	$0.00
YoY Change	-100.02%	-287.83%	-100.0%
Pretax Income	-$2.440M	-$8.755M	-$350.0K
YoY Change	-12.86%	338.54%	-55.7%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.442M	-$8.388M	-$420.0K
YoY Change	-12.8%	440.63%	-51.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$244.00	-$1.662K	-$42.00
COMMON SHARES
Basic Shares Outstanding	8.346M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.210M	$8.390M	$170.0K
YoY Change	214.85%	4835.29%	-66.0%
Cash & Equivalents	$7.215M	$8.390M	$167.0K
Short-Term Investments
Other Short-Term Assets	$750.0K	$120.0K	$30.00K
YoY Change	316.67%	300.0%	50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$337.5K		$0.00
Total Short-Term Assets	$8.330M	$9.450M	$218.8K
YoY Change	234.54%	4195.45%	-60.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$0.00	$1.257K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$46.57K	$60.00K	$37.44K
YoY Change	-22.38%	-94.96%	-71.2%
Total Long-Term Assets	$3.987M	$60.00K	$1.191M
YoY Change	6544.79%	-94.96%	816.32%
TOTAL ASSETS
Total Short-Term Assets	$8.330M	$9.450M	$218.8K
Total Long-Term Assets	$3.987M	$60.00K	$1.191M
Total Assets	$12.32M	$9.510M	$1.410M
YoY Change	383.01%	574.47%	104.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$869.3K	$420.0K	$565.9K
YoY Change	199.77%	-26.32%	5559.47%
Accrued Expenses	$910.7K	$1.100M	$913.1K
YoY Change	600.51%	20.88%	86.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$3.210M
YoY Change		-100.0%	58.13%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.650M	$3.420M	$5.024M
YoY Change	1278.04%	-31.87%	95.49%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.650M	$3.420M	$5.024M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$5.650M	$3.420M	$11.80M
YoY Change	1278.05%	-71.02%	29.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$67.70M		-$56.86M
YoY Change
Common Stock	$83.46K		$2.018K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.667M	$6.090M	-$46.81M
YoY Change
Total Liabilities & Shareholders Equity	$12.32M	$9.510M	$1.406M
YoY Change	383.01%	574.47%	103.84%

Cashflow Statement

Concept	2016 Q1	2015	2014 Q4
OPERATING ACTIVITIES
Net Income	-$2.442M	-$8.388M	-$420.0K
YoY Change	-12.8%	440.63%	-51.16%
Depreciation, Depletion And Amortization	$84.00	$1.257K	$0.00
YoY Change	-75.44%	-27.09%	-100.0%
Cash From Operating Activities	-$1.350M	-$4.460M	-$440.0K
YoY Change	-23.73%	369.47%	-38.89%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$180.0K	-$20.00K
YoY Change	-1000.0%
Cash From Investing Activities	$180.0K	-$20.00K
YoY Change	-1000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$14.10M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	12.62M	320.0K
YoY Change	-100.0%	1968.85%
NET CHANGE
Cash From Operating Activities	-1.350M	-4.460M	-440.0K
Cash From Investing Activities	180.0K	-20.00K
Cash From Financing Activities	0.000	12.62M	320.0K
Net Change In Cash	-1.170M	8.140M	-120.0K
YoY Change	-156.52%	-2494.12%	-83.33%
FREE CASH FLOW
Cash From Operating Activities	-$1.350M	-$4.460M	-$440.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2014Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3205504	USD
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	303102	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3420935	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5024017	USD
CY2015Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0	USD
CY2014Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	6780588	USD
CY2015Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	USD
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	43189254	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	2018	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	71209530	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10055613	USD
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Registrant Name EntityRegistrantName	EYEGATE PHARMACEUTICALS INC
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001372514
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8222008	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16615157	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.70
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6164064	shares
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	1102	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	76573	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65255301	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56862152	USD
CY2014Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	58824	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	114788	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	56544	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	6086766	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-46806801	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	910575	USD
CY2014	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	222484	USD
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015Q2	dei	Entity Public Float EntityPublicFloat	8181230	USD
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Trading Symbol TradingSymbol	EYEG
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8346444	shares
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8394133	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	167001	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	531116	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2717110	USD
CY2015Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	58824	USD
CY2015Q4	eyeg	Grants Payable Current GrantsPayableCurrent	0	USD
CY2014Q4	eyeg	Grants Payable Current GrantsPayableCurrent	36401	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	417697	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	565947	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1095738	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	913063	USD
CY2015Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1907500	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1930967	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3960498	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	2462083	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	6677608	USD
CY2014	eyeg	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	15911	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	947	USD
CY2014	us-gaap	Interest Expense InterestExpense	441720	USD
CY2015	us-gaap	Interest Expense InterestExpense	1934493	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1095282	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1710364	USD
CY2014	us-gaap	Profit Loss ProfitLoss	-1551508	USD
CY2015	us-gaap	Profit Loss ProfitLoss	-8387972	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5177	USD
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	240000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1724	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1257	USD
CY2014	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	USD
CY2015	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	-1663873	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	26815	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1224687	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4092	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	95952	USD
CY2014	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-7294	USD
CY2015	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2357	USD
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1455	USD
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1148	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	552256	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-148250	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	896856	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	265754	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6500	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26826	USD
CY2014	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1148994	USD
CY2015	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1479202	USD
CY2014	eyeg	Proceeds From Convertible Notes Payable ProceedsFromConvertibleNotesPayable	1755767	USD
CY2014	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2015	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-32628	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	613273	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12616256	USD
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	3173	USD
CY2014	eyeg	Loss On Cancellation Of Note Receivable And Related Accrued Interest Receivable LossOnCancellationOfNoteReceivableAndRelatedAccruedInterestReceivable	-200758	USD
CY2015	eyeg	Proceeds From Convertible Notes Payable ProceedsFromConvertibleNotesPayable	0	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	90045	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-334171	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8227132	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	501172	USD
CY2015	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	244111	USD
CY2014	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	226017	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4459169	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-950617	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	20000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-20000	USD
CY2015	eyeg	Loss On Cancellation Of Note Receivable And Related Accrued Interest Receivable LossOnCancellationOfNoteReceivableAndRelatedAccruedInterestReceivable	0	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1907500	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	14101260	USD
CY2014	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-46806801	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	780293	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-36408666	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26826	USD
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	58244	USD
CY2015	eyeg	Stock Issued During Period Value Conversion Of Convertible Securities1 StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1	-6818732	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4099500	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1373858	USD
CY2015	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	3532694	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6086766	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1663873	USD
CY2015	eyeg	Reclassification Of Previously Issued Warrant Liability To Stockholders Equity ReclassificationOfPreviouslyIssuedWarrantLiabilityToStockholdersEquity	79930	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	444394	USD
CY2015	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10001760	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-1254338	USD
CY2015Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4.20
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7657287	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.4999	pure
CY2014Q4	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.4999	pure
CY2014Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5001	pure
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5342137	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3084570	shares
CY2015	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	79930	USD
CY2015	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-223172	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1149000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	268093	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	266836	USD
CY2014	us-gaap	Depreciation Depreciation	1724	USD
CY2015	us-gaap	Depreciation Depreciation	1257	USD
CY2014Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2100000	USD
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50485136	shares
CY2015	eyeg	Convertible Preferred Stock Discount Rate At Initial Public Offering Price ConvertiblePreferredStockDiscountRateAtInitialPublicOfferingPrice	0.3	pure
CY2015	eyeg	Debt Conversion Original Debt Discount Rate At Initial Public Offering Price DebtConversionOriginalDebtDiscountRateAtInitialPublicOfferingPrice	0.3	pure
CY2014	eyeg	Net Extinguished Fair Value Of Stock Consideration Received NetExtinguishedFairValueOfStockConsiderationReceived	240000	USD
CY2015	us-gaap	License Costs LicenseCosts	12500	USD
CY2012Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	100000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	12500	USD
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	900000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M17D
CY2015Q4	eyeg	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue	1382000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	135000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	202000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1597000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	211740	USD
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	60616	shares
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42431	USD
CY2012Q1	eyeg	License Expiration Period LicenseExpirationPeriod	P12Y
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 17.6pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 17.6pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are required in providing for fair value of warrants, establishing useful lives of intangible assets and property and equipment, and conducting impairment reviews of long-lived assets. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3376573	USD
CY2015Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7657287	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	201787	shares
CY2015	eyeg	Conversion Of Stock Conversion Price Per Share ConversionOfStockConversionPricePerShare	6.00
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015	eyeg	Description On Civil Penalties For Failure To File Fbar DescriptionOnCivilPenaltiesForFailureToFileFbar	greater of $100,000 per year or 50%
CY2015	us-gaap	Description Of Lessor Leasing Arrangements Operating Leases DescriptionOfLessorLeasingArrangementsOperatingLeases	The Company executed a 2 year lease agreement commencing in December 2015 and ending in December 2017.
CY2015	eyeg	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	0	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	1224687	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	26815	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	91211	USD
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5510	USD
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	91211	USD
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5510	USD
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-32967	USD
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	1889	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-27790	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	224373	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8268971	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1770371	USD
CY2014	eyeg	Conversion Of Subsidiary Stock Shares Issuable ConversionOfSubsidiaryStockSharesIssuable	1070333	shares
CY2015Q1	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	preferred shares were converted at the ratio of 10.98 shares of the preferred stock to 1.00 share of common stock.
CY2015Q4	eyeg	Money Market Funds Fair Value MoneyMarketFundsFairValue	7200450	USD
CY2014Q4	eyeg	Money Market Funds Fair Value MoneyMarketFundsFairValue	187	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	268093	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	268093	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-44843839	USD
CY2014	eyeg	Cancellation Of Shareholder Note Receivable CancellationOfShareholderNoteReceivable	136176	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26815	USD
CY2014	eyeg	Adjustments To Additional Paid In Capital Loss On Modification And Extinguishment AdjustmentsToAdditionalPaidInCapitalLossOnModificationAndExtinguishment	668000	USD
CY2014	eyeg	Adjustments To Additional Paid In Capital Gain On Troubled Debt Restructuring AdjustmentsToAdditionalPaidInCapitalGainOnTroubledDebtRestructuring	200918	USD
CY2014	eyeg	Stock Issued During Period Value Settlement Of Liability StockIssuedDuringPeriodValueSettlementOfLiability	105000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6500	USD
CY2014	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	3621	USD
CY2014	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	0	USD
CY2015	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	1148994	USD
CY2014	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	0	USD
CY2015	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	79930	USD
CY2014	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	0	USD
CY2015Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4.20
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	907500	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2015	eyeg	Conversion Of Non Controlling Interests To Commonstock ConversionOfNonControllingInterestsToCommonstock	6818732	USD
CY2014	eyeg	Conversion Of Non Controlling Interests To Commonstock ConversionOfNonControllingInterestsToCommonstock	0	USD
CY2015	eyeg	Conversion Of Preferred Stock Into Common Stock ConversionOfPreferredStockIntoCommonStock	36408666	USD
CY2014	eyeg	Conversion Of Preferred Stock Into Common Stock ConversionOfPreferredStockIntoCommonStock	0	USD
CY2015	eyeg	Exercise Of Common Warrants ExerciseOfCommonWarrants	97	USD
CY2014	eyeg	Exercise Of Common Warrants ExerciseOfCommonWarrants	0	USD
CY2015	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	3532694	USD
CY2014	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2015	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	8222008	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1398384	USD
CY2015	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2014	us-gaap	Stock Issued1 StockIssued1	105000	USD
CY2015	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
CY2014	us-gaap	Notes Assumed1 NotesAssumed1	127782	USD
CY2015	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">1. Nature of Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 17.6pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 17.6pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">EyeGate Pharmaceuticals, Inc. (“EyeGate” or the “Company”), a Delaware corporation, began operations in December 2004 and is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EyeGate’s first product in clinical trials incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues though our proprietary innovative drug delivery system, the EyeGate® II Delivery System.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 17.6pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 20.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On February 13, 2015, the Company completed an initial public offering (“the IPO”) for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 683,250</font> shares of common stock. The common stock was offered at an initial price to the public of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.00</font> per share. The gross proceeds to the Company from this offering was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,100,000</font> before deducting underwriting discounts and other estimated offering expenses. The shares began trading on the OTCQB Venture Marketplace under the symbol “EYEG” on February 13, 2015 and the initial offering was closed on February 19, 2015. In related transactions, the Company converted all outstanding notes payable to shareholders and all shares of its convertible preferred stock to shares of common stock. The notes were converted to common shares at the discounted price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.20</font> per share and the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">preferred shares were converted at the ratio of 10.98 shares of the preferred stock to 1.00 share of common stock.</font> As of December 31, 2015, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,657,287</font> shares of common stock outstanding at a par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font>. All preferred stock, shareholder notes and warrant liabilities have been extinguished. On August 5, 2015, the Company closed an underwritten secondary public offering of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,176,470</font> shares of its common stock and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,176,470</font> shares of its common stock at a combined public offering price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.50</font> per share of common stock and warrant, before underwriting discounts and commissions. The warrants have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.62</font> per share, are immediately exercisable, and expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">August 5, 2020</font>.  At the closing of the offering, the Company also issued and sold additional warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 176,470</font> shares of common stock in connection with the full exercise of the underwriters’ over-allotment option to purchase additional warrants. The net proceeds to the Company were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.8</font> million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 20.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 20.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Since its inception, EyeGate has devoted substantially all of its efforts to business planning, research and development, and raising capital.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 20.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 20.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The accompanying consolidated financial statements have been prepared assuming that EyeGate will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At December 31, 2015, EyeGate has cash and cash equivalents of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,394,133</font>, and an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,255,301</font>. EyeGate has incurred operating losses and negative operating cash flows since inception, and future losses are anticipated. The Company estimates it will have sufficient cash to fund planned operations for approximately 12 to 15 months, however, the acceleration or reduction of cash outflows by management can significantly impact the timing for raising additional capital to complete development of its products. To continue development, EyeGate will need to raise additional capital through debt and/or equity financing, or access additional funding through grants. Although the Company completed the IPO and Secondary Offering, additional capital may not be available on terms favorable to EyeGate, if at all. Accordingly, no assurances can be given that management will be successful in these endeavors. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	907500	USD
CY2014Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	USD
CY2015Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	38587	USD
CY2014Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	1186433	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	All outstanding shares of Series A, B, C and D preferred stock automatically converted to common stock immediately upon the closing of the Company’s initial public offering in February 2015 at the conversion rates of 1:0.251, 1:0.091, 1:0.091, and 1:0.091, respectively.
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2015	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	USD
CY2014	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	30000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1996387	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	367038	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	444879	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-8755011	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8387973	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1551508	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0627	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0627	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.1088	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.5055	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2955	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.8454	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0043	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.1252	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0024	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0260	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2015	eyeg	Expiration Of State Net Operating Loss Carryforward Percent ExpirationOfStateNetOperatingLossCarryforwardPercent	-0.0003	pure
CY2014	eyeg	Expiration Of State Net Operating Loss Carryforward Percent ExpirationOfStateNetOperatingLossCarryforwardPercent	-0.1620	pure
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18050019	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15491353	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1226384	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1190024	USD
CY2015Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4452114	USD
CY2014Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4823160	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	164292	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	100712	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	587	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	587	USD
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	137	USD
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	17959	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	26938	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2179356	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1979847	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26090848	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23612621	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26090848	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23612621	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2015	eyeg	Operating Loss Carryforwards Expiration Period OperatingLossCarryforwardsExpirationPeriod	2035
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2478000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1312000	USD

Files In Submission

Name	View Source	Status
0001144204-16-091485-index-headers.html	Edgar Link	pending
0001144204-16-091485-index.html	Edgar Link	pending
0001144204-16-091485.txt	Edgar Link	pending
0001144204-16-091485-xbrl.zip	Edgar Link	pending
eyeg-20151231.xml	Edgar Link	completed
eyeg-20151231.xsd	Edgar Link	pending
eyeg-20151231_cal.xml	Edgar Link	unprocessable
eyeg-20151231_def.xml	Edgar Link	unprocessable
eyeg-20151231_lab.xml	Edgar Link	unprocessable
eyeg-20151231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v434534_10k.htm	Edgar Link	pending
v434534_ex10-11.htm	Edgar Link	pending
v434534_ex21-1.htm	Edgar Link	pending
v434534_ex23-1.htm	Edgar Link	pending
v434534_ex31-1.htm	Edgar Link	pending
v434534_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KPRX
KIORA PHARMACEUTICALS INC Stock $kprx

2016 Q1 Form 10-K Financial Statement

#000114420416091485 Filed on March 30, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPRX KIORA PHARMACEUTICALS INC Stock $kprx

2016 Q1 Form 10-K Financial Statement

#000114420416091485 Filed on March 30, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPRX
KIORA PHARMACEUTICALS INC Stock $kprx